Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Michael S Diamond · WASHINGTON UNIVERSITY · 2022 · $950,300 — PROJET SUMMARY/ABSTRACT Globally, the four serotypes of DENV cause an estimated 390 million new cases of dengue fever and 500,000 cases of dengue hemorrhagic fever (DHF) per year. Zika virus (ZIKV) is a related emerging virus linked to Guillain-Barre syndrome in adults, and microcephaly, congenital …
Patricia DEVAUX · MAYO CLINIC ROCHESTER · 2022 · $318,000 — Abstract. The recent advances in induced pluripotent stem cells (iPSCs) and gene therapy tools have opened up a new avenue to study and treat diseases, particularly of disorders with defective bone marrow. Bone marrow failure syndromes (BMFS) are characterized by reduced blood cells due to a dysfunc…
Thale Cross Jarvis · KEYSTONE SYMPOSIA · 2022 · $5,500 — ABSTRACT Support is requested for a Keystone Symposia conference entitled Progress in Vaccine Development for Infectious Diseases, organized by Drs. Katalin Kariko, Karin Loré and Norbert Pardi. The conference will be held in Breckenridge, Colorado from June 1-4, 2022. Vaccines are the cornerstones …
Annaliese Franz · UNIVERSITY OF CALIFORNIA AT DAVIS · 2022 · $73,558 — PROJECT ABSTRACT Liposomes, including nucleic acid complexed lipid nanoparticles (LNPs) have shown success in drug delivery and formulation of sensitive RNA-based therapeutics, including the recent example of the mRNA Sar-COV-2 vaccine. The goal of this proposal is to synthesize and evaluate novel s…
NASSER Khaled ALTORKI · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $1,180,595 — Overall Component: Project Summary/Abstract The overall goal of CAP-IT Center for RNA Immunoprevention (CRI) is to pre-clinically delineate, formulate and validate liponanoparticle RNA (LNP RNA) vaccines for precision prevention of individuals with increased cancer risk. The PI is Dr. Lipkin, an est…
Laura Su · UNIVERSITY OF PENNSYLVANIA · 2022 · $602,727 — Project Summary An ongoing outbreak of a novel coronavirus infection (COVID-19) has claimed millions of lives and disrupted social infrastructures around the world. Fortunately, the new mRNA vaccines from Moderna or Pfizer/BioNTech are highly effective against SARS-CoV-2. However, much remains unkno…
Roger L Shapiro · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2022 · $1,214,934 — Overall Project Summary/Abstract Antiretroviral treatment (ART) options for pregnant women and children living with HIV have fallen behind those for adults, reflecting the substantial research gap for modern ART regimens in these groups. Safety and efficacy studies of specific ART regimens in pregna…
MIKELL PAIGE · GEORGE MASON UNIVERSITY · 2022 · $491,446 — PROJECT SUMMARY mRNA vaccines have received emergency authorization approval for Covid-19 and are under development for several other infectious diseases. The mRNA-encoded immunogen in these vaccines is delivered inside a lipid nanoparticle (LNP) that comprises four lipids, the most important being …
CHIUNG-YU HUNG · UNIVERSITY OF TEXAS SAN ANTONIO · 2022 · $1,357,000 — Summary (Overall) San Antonio has a rich tradition of excellence in the field of Medical Mycology, including Coccidioidomycosis, also referred to as Valley Fever. These infections affect hundreds of thousands of healthy and immunocompromised individuals in the endemic areas of the arid Southwest U.S…
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $1,375,878 — ABSTRACT – Overall Nearly 600,000 new HIV infections occur yearly in adolescents/young adults (ages 15-24 years), the only population in which HIV infections continue to rise. The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can elicit long-term protective i…
Ken A Halvorsen · STATE UNIVERSITY OF NEW YORK AT ALBANY · 2022 · $460,856 — Project Summary Our vision is to develop, apply, and advance new technologies in the broad thematic program of the manipulation of nucleic acids. The research largely focuses on RNA-based applications, which is both driven and enhanced by our unique environment at The RNA Institute, enabling easy co…
Rachel Fearns · BOSTON UNIVERSITY MEDICAL CAMPUS · 2022 · $529,563 — Marburg virus (MARV) belongs to the filovirus family and is highly pathogenic in humans. Despite being classified as Category A Priority Pathogen by NIAID, and its potential to cause large-scale outbreaks, similar to the recent Ebola virus outbreak, research on MARV lags significantly behind that on…
Richard B Kennedy · MAYO CLINIC ROCHESTER · 2022 · $772,439 — PROJECT SUMMARY/ABSTRACT This application is a request for funding of a research program focused on understanding the factors associated with waning immune response to mumps vaccine. Waning immunity to mumps is a public health concern and a major obstacle in the control and elimination of mumps dise…
Rachel Fearns · BOSTON UNIVERSITY MEDICAL CAMPUS · 2021 · $529,282 — Marburg virus (MARV) belongs to the filovirus family and is highly pathogenic in humans. Despite being classified as Category A Priority Pathogen by NIAID, and its potential to cause large-scale outbreaks, similar to the recent Ebola virus outbreak, research on MARV lags significantly behind that on…
Henry Charles Mwandumba · CORNELL UNIVERSITY · 2021 · $659,438 — Our recent advances in the use of fluorescent fitness reporter Mtb strains in the murine TB model has afforded us a unique appreciation of the role of macrophage lineages in both the control and promotion of Mtb growth. Moreover, the extension of these observations through the successful development…
Shinji Makino · UNIVERSITY OF TEXAS MED BR GALVESTON · 2021 · $309,206 — Coronaviruses (CoVs), which carry a large, single-stranded, positive-sense RNA genome, cause a variety of diseases in humans and domestic animals. Human CoVs (HCoVs) usually infect the respiratory tract and cause a range of symptoms varying from mild, such as the common cold, to more serious respira…
YASUHIRO SUZUKI · UNIVERSITY OF KENTUCKY · 2021 · $459,000 — Chronic infection with Toxoplasma gondii can reactivate and cause life-threatening toxoplasmic encephalitis in AIDS patients and other immunocompromised individuals. The basis of persistence of this chronic infection is the tissue cyst. Thus, eliminating T. gondii cysts from chronically infected ind…
Richard John Martin · IOWA STATE UNIVERSITY · 2021 · $469,119 — Project Summary Filariases are a group of neglected tropical diseases produced by infection with microfilaria of Clade III parasitic nematodes that are transmitted by biting insects. One example is the lymphatic filariasis produced by Brugia malayi. Lymphatic filariasis is a debilitating and disfigu…
Dusan Bogunovic · LAB11 THERAPEUTICS, LLC · 2021 · $255,932 — Project Summary Currently there are very few antiviral drugs, and no broad-spectrum antiviral drugs. For example, Influenza A virus (IAV) causes 12,000-56,000 deaths and 150,000-750,000 hospitalizations annually in the US alone, despite the availability of vaccines and five FDA-approved drugs 1, 2. …
WILLIAM R. SCHIEF · SCRIPPS RESEARCH INSTITUTE, THE · 2021 · $904,630 — Induction of broadly neutralizing antibodies (bnAbs) is a critical unmet goal of HIV vaccine development. BnAb 10E8 is of particular interest as a vaccine lead due to its (1) very high breadth, (2) low number of mutations required to develop broad neutralization, (3) low auto-reactivity, (4) expe…